Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.36 |
| ▸ | FABP7 | O15540 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17265629 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BPPARGPPARAFABP5 | |
| SCHEMBL31437117 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BPPARGPPARAFABP5 | |
| SCHEMBL31037194 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BPPARGPPARAFABP5 | |
| SCHEMBL31037195 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BPPARGPPARAFABP5 | |
| SCHEMBL16482875 | 0.91 | ITGB3 (0.39) | ITGB3ITGA2BPPARGPPARAFABP5 | |
| SCHEMBL25185646 | 0.91 | ITGB3 (0.45) | ITGB3ITGA2BPPARGPPARAFABP5 | |
| SCHEMBL25185647 | 0.91 | ITGB3 (0.45) | ITGB3ITGA2BPPARGPPARAFABP5 | |
| SCHEMBL29855055 | 0.91 | ITGB3 (0.45) | ITGB3ITGA2BPPARGPPARAFABP5 | |
| SCHEMBL25357586 | 0.89 | ITGB3 (0.40) | ITGB3ITGA2BPPARGPPARAFABP5 | |
| SCHEMBL25357591 | 0.89 | ITGB3 (0.40) | ITGB3ITGA2BPPARGPPARAFABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025070720-A1 | PEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025070731-A1 | PEPTIDEPEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025047793-A1 | NOVEL COMPOUND HAVING ACTIVITY-ENHANCING EFFECT ON ANTIFUNGAL DRUGS, AND METHOD FOR PRODUCING SAME | 学校法人北里研究所 | 2025-03-06 | — | — | WO | disclosed |
| EP-4347618-B1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH INC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-12 | — | — | US | disclosed |
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-22 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-110183514-B | Multi-target peptide molecules of opioid and neuropeptide FF receptors and preparation and application thereof | 上海天慈生命科学发展有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022256380-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-21 | — | — | US | disclosed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-9493512-B2 | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20150218224-A1 | Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| US-9067978-B2 | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG (CH) | 2015-06-30 | — | — | US | disclosed |
| US-20140100355-A1 | Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | NOVARTIS AG (CH) | 2014-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | ITGB3 3636/4885ITGA2B 3216/4885PPARG 509/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | ITGB3 1361/4885ITGA2B 2376/4885PPARG 544/4885 |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | ITGB3 3586/4885ITGA2B 3315/4885PPARG 325/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | ITGB3 3655/4885ITGA2B 3347/4885PPARG 354/4885 |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | ITGB3 4095/4885ITGA2B 3686/4885PPARG 493/4885 |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, VIPR1 | ITGB3 4757/4885ITGA2B 4496/4885PPARG 515/4885 |
| US-20140100355-A1 | Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | VIP, NPPA, DNPEP | ITGB3 4866/4885ITGA2B 4782/4885PPARG 4604/4885 |
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | GIPR, GLP1R, GPR119 | ITGB3 4685/4885ITGA2B 4245/4885PPARG 434/4885 |
| US-20150218224-A1 | Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | VIP, NPPA, DNPEP | ITGB3 4866/4885ITGA2B 4782/4885PPARG 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.